drugset
drugset / Trial / NCT00186849

Therapy for Children With Advanced Stage High Risk Neuroblastoma

NCT00186849 ↗

Phase 2 Completed 30 enrolled St. Jude Children's Research Hospital National Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.

Timeline

Start
1997-10
Primary completion
2001-04
Completion
2001-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 700 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 40 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 1 g Intravenous
Subject Doxorubicin Other / unclassified 35 mg/m2 —
Subject Etoposide Small molecule 30 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 200 mg/m2 Intravenous
Subject Etoposide Small molecule 250 mg/m2 Intravenous
Subject Etoposide Small molecule 500 mg/m2 Intravenous
Subject Ifosfamide Small molecule 2 g Intravenous
Subject Topotecan Small molecule 3 mg/m2 Intravenous

Indications

neuroblastoma